Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
about
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsMapping genes that predict treatment outcome in admixed populationsThe relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.Vorapaxar: a novel protease-activated receptor-1 inhibitor.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Long-term acid inhibition: benefits and harms.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.Cigarette smoking and clopidogrel interaction.Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism.Determinants to optimize response to clopidogrel in acute coronary syndromePersonalized healthcare in clotting disorders.The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitroInteraction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases.Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
P2860
Q26771106-B9C86688-37FF-4659-A233-346EA26C5404Q34348337-CCCAD1D2-EAB5-44B8-8021-828B9C8ABFA7Q34703779-75D9C244-E861-4523-8CA7-45C387123E53Q35048059-666F410F-22F0-45CD-9D53-38218D5953F0Q35176063-19BB3C3D-FA40-474C-842C-D73C310D1517Q35648335-94664D49-49D2-4107-A6F9-CE6954A1903DQ36039469-60A0FE7B-480F-4DD2-91D4-19D9CC21B959Q37387416-6C07E96A-8B46-43D4-B5C0-196983FEDFFEQ37693951-41D915F8-4551-42E6-80EF-D2157CFCDFC6Q37907918-44818771-A912-4038-99AA-59BE83CB3E7AQ37912186-6C6C005A-26DE-4E4D-BCBA-BFC24E923D5AQ37923969-03113CBA-74D2-46E2-AB83-3D42E5FC57EAQ37957704-BF9B7ABC-33F6-49A6-BBD1-B72309ECC37FQ38012079-12AA411A-70AF-4F4A-A426-E4FF32AF36D2Q38048837-377583F7-F288-40D9-B751-47FE55224FA9Q38099541-A722F153-3068-4DF4-806A-19C88D216B34Q38243854-4338EE42-0B5C-42A7-A9C6-9408906785F3Q41511099-64CA1C89-E793-4F4B-9C6F-BC07485A312CQ41751908-498BA5A0-BB54-447E-9C96-5A2CB0B4F50CQ41848961-5257FB85-3A98-4EF8-85C7-EB138E1EBFDBQ41960992-9E531696-A852-4030-9F68-D8F85A68D3A9Q42326752-FAC1C5C8-9DD9-4E38-A8EB-9C33726B1391Q42731681-CBD170FB-26AB-408F-A90F-87FE835889DCQ42748476-2E436216-CD82-4F0A-94D1-1AE3E2D91FDDQ44986245-60002310-CF90-4054-88C4-4E7687FBBEC5Q58071120-D2BD15F4-DBD6-4D7F-9164-75F10DECCD06
P2860
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@en
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@nl
type
label
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@en
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@nl
prefLabel
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@en
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@nl
P2093
P2860
P1476
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
@en
P2093
Mark J Antonino
Paul A Gurbel
Udaya S Tantry
P2860
P304
P356
10.1517/17425250903107772
P407
P577
2009-08-01T00:00:00Z